









Markets
/
Stocks
/
nasdaq-lenz
/

LENZ Therapeutics Inc

LENZ

View Detailed Chart

28.170USD

-1.790-5.97%

Market hours （ET）Quotes delayed by 15 min

802.85MMarket Cap

LossP/E TTM



LENZ Therapeutics Inc

28.170

-1.790-5.97%

Overview Company Financials

Financials

Intraday

30m

Today

-5.97%

5 Days

-10.91%

1 Month

-13.40%

6 Months

+11.04%

Year to Date

-2.42%

1 Year

+17.28%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts

STRONG BUY

Current Rating

48.571

Target Price

62.12%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

LENZ Therapeutics Inc

LENZ

Apple Inc

AAPL

Lyft Inc

LYFT

GE Vernova Inc

GEV

UnitedHealth Group Inc

UNH

Cigna Group

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(7)

Neutral(2)

Buy(1)

Indicators

Sell(2)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.139

Neutral

RSI(14)

41.137

Neutral

STOCH(KDJ)(9,3,3)

10.975

Oversold

ATR(14)

1.997

Low Volatility

CCI(14)

-142.011

Sell

Williams %R

86.026

Oversold

TRIX(12,20)

0.092

Sell

StochRSI(14)

13.678

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

30.734

Sell

MA10

31.830

Sell

MA20

32.744

Sell

MA50

30.904

Sell

MA100

28.161

Buy

MA200

28.242

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.

Ticker SymbolLENZ

CompanyLENZ Therapeutics Inc

CEOMr. Evert (Eef) Schimmelpennink

Website